Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostics firm focused on early cancer detection, announced a $8 million follow-on offering. This offering comprises 1,367,521 units, each including one ordinary share (or prefunded warrant), one Series A warrant, and one Series B warrant. The units are priced at $5.85 each, in accordance with Nasdaq’s at-the-market rules. Both Series A and Series B warrants have an exercise price of $5.85 per share and are immediately exercisable. Series A warrants expire in five years, while Series B warrants expire either 30 days after the Company’s eAArly Detect 2 study results or one year from issuance, whichever comes first.

Maxim Group LLC is the sole placement agent. The offering is slated to close around December 16, 2024, pending standard closing conditions.

These securities were offered under an amended Form F-1 registration statement (File No. 333-282993), declared effective by the SEC on December 12, 2024. The offering was made via a prospectus, part of the Registration Statement. A final prospectus is available from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, (212) 895-3745. This press release isn’t an offer to sell or a solicitation to buy securities where prohibited by law.

For more information, visit Mainz Biomed’s investor relations page at mainzbiomed.com/investors/

About Mainz Biomed NV
Mainz Biomed develops molecular genetic diagnostic tools for life-threatening diseases. Its flagship product, ColoAlert®, is a non-invasive colorectal cancer early detection test marketed in Europe and currently undergoing pivotal FDA trials for US approval. The company also develops PancAlert, a pancreatic cancer screening test. For more details, visit mainzbiomed.com.

For media inquiries

MC Services AG
Anne Hennecke/Caroline Bergmann
+49 211 529252 20
mainzbiomed@mc-services.eu

For investor inquiries, contact info@mainzbiomed.com

Forward-Looking Statements

This press release contains forward-looking statements, subject to risks and uncertainties under the Private Securities Litigation Reform Act of 1995. These statements, often including words like “anticipate,” “believe,” “expect,” etc., predict future events and are based on current information. Actual results may differ materially due to factors such as unmet development targets, regulatory changes, the impact of the COVID-19 pandemic, and other risks detailed in the Company’s SEC filings, including its Form 20-F filed April 9, 2024, available at www.sec.gov. These statements reflect Mainz Biomed’s current views and are only valid as of today’s date. Mainz Biomed doesn’t commit to updating them unless legally required.